Last updated on November 2018

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)


Brief description of study

This study will investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with BPH.

Detailed Study Description

Fedovapagon is a selective vasopressin V2 receptor (V2R) agonist that has an antidiuretic effect through stimulation of V2 receptors in the kidney and is being developed for the treatment of nocturia. Nocturia, defined as the complaint that the individual has to wake at night one or more times to void, is a common condition and shows an age-dependent increase in both prevalence and severity (number of nocturnal voids). It has a significant detrimental impact on the quality of life in patients with benign prostatic hyperplasia (BPH). The purpose of this study is to determine the efficacy and safety of fedovapagon in the treatment of nocturia with BPH.

Clinical Study Identifier: NCT02637960

Contact Investigators or Research Sites near you

Start Over

Clinical Development Support

Vantia Investigative Center
Hialeah, FL United States

Clinical Development Support

Vantia Investigative Center
Miami, FL United States
8.53miles

Clinical Development Support

Vantia Investigative Center
Coral Gables, FL United States
9.42miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.